While approved BRAF inhibitors (BRAFi) provide survival benefit to Class 1 patients, drug durability and efficacy are limited by the emergence of primary and acquired resistance. Furthermore ...

While BRAF inhibitors (such as vemurafenib ... dynamic adaptation process that occurs within hours to days of drug treatment—long before genetic resistance takes hold. Surprisingly, this ...

A new research perspective was published in Oncotarget, Volume 16, on April 4, 2025, titled “GSK3β activation is a key driver of resistance to Raf inhibition in BRAF mutant melanoma cells.” ...

The pairing of the BRAF inhibitor and anti-EGFR antibody was approved by the EMA in June on the back of the BEACON CRC trial, which showed a median overall survival of 9.3 months for the two-drug ...

Compared to acquired mutations driving resistance to early generation BRAF inhibitors, no new mutations in MAPK pathway genes were found following plixorafenib treatment, supporting the dimer ...

While treatments targeting BRAF, known as BRAF inhibitors, initially work well ... The research perspective adds to ongoing efforts to understand and overcome melanoma drug resistance. It shows that ...

While BRAF inhibitors (such as vemurafenib ... dynamic adaptation process that occurs within hours to days of drug treatment – long before genetic resistance takes hold. Surprisingly, this ...

While treatments targeting BRAF, known as BRAF inhibitors, initially work well ... ongoing efforts to understand and overcome melanoma drug resistance. It shows that resistance is not driven ...